• Explore /
  • Poster
  • / Phase I study of peptide vaccine targeting indeolamine 2,3 dioxygenase in metastatic lung cancer patients.

Phase I study of peptide vaccine targeting indeolamine 2,3 dioxygenase in metastatic lung cancer patients.

Abstract Poster

Authors

null

Trine Zeeberg Iversen

Department of Oncology and Center for Cancer ImmuneTherapy, Department of Hematology, Copenhagen University Hospital Herlev, Herlev, Denmark

Trine Zeeberg Iversen , Lotte Engell-Noerregaard , Eva Ellebaek , Rikke Andersen , Stine Kiaer Larsen , Jon Bjoern , Merete Jonassen , Hubert Kalbacher , Claus Zeyher , Cecile Gouttefangeas , Inger Birthe Moerk Thomsen , Bente Holm , Anders Mellemgaard , Per thor Straten , Mads Hald Andersen , Inge Marie Svane

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer - Non-small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT01219348

Citation

J Clin Oncol 31, 2013 (suppl; abstr 8084)

DOI

10.1200/jco.2013.31.15_suppl.8084

Abstract #

8084

Poster Bd #

37H

Abstract Disclosures

Similar Posters

First Author: Yang Zhang

First Author: Craig L. Slingluff Jr.

First Author: Sumana Veeravelli

First Author: Michael Bitzer